Investors appear to be expecting Mannkind’s chief executive and majority shareholder, Alfred Mann, to be true to his word and deliver a big pharma partnership for the company’s inhaled insulin product, Afresa; a deal which Mr Mann hopes to have signed by the end of the year, but could even be announced within the next few weeks (Mannkind CEO predicts deal for inhaled insulin product by September, May 6, 2009).Since the start of September Mannkind’s shares have surged 55% to reach a two-year high of $11.81, driven mainly by high trading volumes, valuing the company at an impressive $1.3bn. Expectations over both Afresa’s commercial opportunity and for the company securing a major partnership are clearly sky-high at the moment. Any delays in landing a deal and anything less than a big pharma partner could leave investors disappointed.
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.